Correlation Between Pharming Group and Dow Jones

Can any of the company-specific risk be diversified away by investing in both Pharming Group and Dow Jones at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharming Group and Dow Jones into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pharming Group NV and Dow Jones Industrial, you can compare the effects of market volatilities on Pharming Group and Dow Jones and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharming Group with a short position of Dow Jones. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharming Group and Dow Jones.

Diversification Opportunities for Pharming Group and Dow Jones

0.06

Correlation Coefficient

Pharming Group  Dow Jones

Significant diversification

The 3 months correlation between Pharming and Dow is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Pharming Group NV and Dow Jones Industrial in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dow Jones Industrial and Pharming Group is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharming Group NV are associated (or correlated) with Dow Jones. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dow Jones Industrial has no effect on the direction of Pharming Group i.e., Pharming Group and Dow Jones go up and down completely randomly.

Pair Corralation between Pharming Group and Dow Jones

Assuming the 90 days trading horizon Pharming Group NV is expected to generate 4.51 times more return on investment than Dow Jones. However, Pharming Group is 4.51 times more volatile than Dow Jones Industrial. It trades about 0.1 of its potential returns per unit of risk. Dow Jones Industrial is currently generating about 0.1 per unit of risk. If you would invest  70.00  in Pharming Group NV on September 18, 2024 and sell it today you would earn a total of  13.00  from holding Pharming Group NV or generate 18.57% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.46%
Values	Daily Returns

Pharming Group NV  vs.  Dow Jones Industrial

Pair Trading with Pharming Group and Dow Jones

The main advantage of trading using opposite Pharming Group and Dow Jones positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharming Group position performs unexpectedly, Dow Jones can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dow Jones will offset losses from the drop in Dow Jones' long position.

The idea behind Pharming Group NV and Dow Jones Industrial pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.